U.S. License Holder:
Macrogenics Inc.
Date of License:
December-16-2020
Last Update:
Dec-15-2024
FDA-Approved Indications
MARGENZA (margetuximab-cmkb) is a HER2/neureceptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.